Biomerica, a microcap Delaware-incorporated diagnostic test developer that has not produced an annual operating profit in recent years, took an atypical step in late May: it agreed to sell the roughly six-percent stake it held in a Polish medical-products distributor, Diagnosis S.A., back to buyers affiliated with Chief Executive Officer Zackary Irani, in exchange for a secured promissory note that bears interest and matures in mid-2027, with the principal and most of the interest forgiven upon successful share transfer. The transaction, disclosed in a current report filed in early June, marks a quiet but loaded related-party move at a company whose own operations continue to consume cash, and the structure of the deal, with interest forgiven only if Polish regulatory approvals complete on a short timeline, makes the recovery of the headline value contingent on an outcome Biomerica itself does not directly control.
The strategic implication is that the company is monetizing a non-core European asset to buy itself operating runway, but it is doing so on terms that make the chief executive a counterparty rather than a beneficiary, and the resulting balance-sheet position, with cash of roughly $1.3 million against an accumulated deficit of approximately $55.8 million, leaves very little cushion relative to the cash-burn profile of the underlying diagnostic business. The equity, with only about three million shares outstanding after a one-for-eight reverse split the company completed in early fiscal 2026, has the kind of share-count and balance-sheet profile that amplifies every material event, positive or negative, into a meaningful move in the share price.
The principal question for the next twelve months is whether Biomerica can advance its two proprietary diagnostic platforms, the inFoods Irritable Bowel Syndrome product line and the recently cleared hp+detect H. pylori test, fast enough to drive a sustained revenue inflection, or whether the company needs a further balance-sheet event to extend its runway past the maturity of the note issued to the Irani-affiliated buyers. The disclosure cadence that the next several quarters resolve is, in order of importance, the completion of the Polish regulatory approval, the commercial adoption pace of the two proprietary platforms, the cash position at the end of the current fiscal year, and any further financing or related-party transaction.